Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCL

Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.

Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Diego Villa, MD, FRCPC Source Type: news